Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catabasis Pharmaceuticals has announced that the US Patent and Trademark Office issued three new patents titled “Fatty acid acetylated salicylates and their uses”, incorporating composition of matter and method of use claims related to the CAT-1000 series of molecules for the treatment of inflammatory disorders.
Subscribe to our email newsletter
The newly-issued patents are: US 8,729,293, US 8,735,378 and US 8,735,379. The method of use claims in these patents cover multiple inflammatory disease indications, including Duchenne muscular dystrophy (DMD).
"The composition of matter and method of use claims in these new patents help to validate our unique chemistry platform and provide our CAT-1000 molecules with broad intellectual property protection," said Michael Jirousek, Ph.D., co-founder and chief scientific officer of Catabasis.
"The CAT-1000 series leverages our SMART (Safely Metabolized and Rationally Targeted) linker conjugation technology to create new molecules with improved efficacy, safety and tolerability profiles for the treatment of inflammatory disorders and rare diseases."
The CAT-1000 series of molecules are oral small molecule drug candidates designed to modulate NF-kB, a central mediator of inflammation, by simultaneously inhibiting pro-inflammatory pathways and activating endogenous anti-inflammatory pathways. Catabasis’ lead CAT-1000 development program, CAT-1004, was designed using Catabasis’ proprietary SMART linker technology to conjugate two NF-kB modulators, salicylate and docosahexaenoic acid (DHA), to enable selective intracellular delivery and synergistic activity.